Lunai Bioworks (LNAI) Q4 2025 earnings summary

Executive summary

• Operates through three subsidiaries focused on AI-driven cancer diagnostics, immunotherapies, and precision medicine; recent acquisitions of GEDi Cube Intl and BioSymetrics Inc. have shifted focus to AI and data-driven platforms.

• No sales revenue generated to date; operations funded by equity and debt; company remains pre-clinical and pre-revenue.

• Significant restructuring, cost reductions, and workforce streamlining to focus on core AI and oncology platforms.

Financial highlights

• Net loss for FY2025 was $178.0 million, up 101% from $88.4 million in FY2024, primarily due to a $158.8 million non-cash goodwill impairment.

• Operating expenses rose 131% to $189.0 million, driven by goodwill impairment; general and administrative expenses decreased 27% to $17.9 million; R&D expenses decreased 80% to $0.5 million.

• Cash and cash equivalents at June 30, 2025, were $92,700, with a working capital deficit of $28.1 million.

• Accumulated deficit reached $510.5 million as of June 30, 2025.

• No revenues recognized; company remains pre-revenue.

Outlook and guidance

• Substantial doubt exists about ability to continue as a going concern; additional funding is required to sustain operations and pursue commercialization.

• Management plans to seek further equity or debt financing; failure to secure funding may result in reduced or suspended operations.

• Focus remains on development and validation of AI-driven cancer diagnostics and precision medicine platforms.